On Monday, Scotiabank reaffirmed its Sector Outperform rating and $13.00 stock price target for Tempest Therapeutics (NASDAQ:TPST), a biopharmaceutical company. The endorsement follows the announcement of Tempest's supply agreement with Roche for atezolizumab, a crucial component in Tempest's upcoming Phase 3 trial.
The trial, which is set to commence patient enrollment in the first quarter of 2025, will evaluate amezalpat in combination with atezolizumab/bevacizumab as a first-line treatment for hepatocellular carcinoma (HCC). The agreement with Roche is expected to alleviate any potential supply constraints for the trial and reduce its costs by $30 million to $50 million, according to Tempest management.
Despite the cost savings, Tempest is still responsible for funding 100% of the trial's expenses. Scotiabank noted that this financial burden may present challenges for the company in raising the necessary funds through the capital markets, given its current valuation. Alternative funding strategies, such as project-based financing and strategic partnerships, alongside an equity raise, are suggested as viable options for securing the necessary capital.
Scotiabank's outlook for Tempest is positive, with the analyst expressing confidence in the potential of amezalpat to become a new standard of care for HCC patients. This optimism is reflected in the continued Sector Outperform rating for Tempest's shares.
In other recent news, Tempest Therapeutics has made significant strides in its cancer treatment development. The biotechnology firm has entered a drug supply agreement with Roche for a Phase 3 study in first-line Hepatocellular Carcinoma.
This partnership builds on a prior clinical collaboration, with Roche supplying the drug and Tempest sponsoring the study. The U.S. Food and Drug Administration (FDA) has approved the Phase 3 study plan, potentially reducing the timeline to primary analysis by eight months.
The company has also appointed Troy M. Wagner as Vice President of Quality Assurance, a strategic move as the company prepares for the upcoming trials. In relation to the financial aspect, Tempest Therapeutics acknowledges the need for significant funding to support the Phase 3 study, with costs estimated around $100 million. The partnership with Roche is expected to reduce expenses by an estimated $30-50 million.
Analysts from H.C. Wainwright has reaffirmed their confidence in the company, maintaining Buy and Sector Outperform ratings on Tempest Therapeutics shares. These recent developments underscore the company's continued progress in the field of cancer treatment.
InvestingPro Insights
Recent InvestingPro data sheds light on Tempest Therapeutics' financial position and market performance, providing context to Scotiabank's analysis. The company's market capitalization stands at a modest $25.46 million, reflecting its early-stage status in the biopharmaceutical sector. Tempest's stock has experienced significant volatility, with a 27.3% decline in the past week and a 71.84% drop over the last year, currently trading at just 11.11% of its 52-week high.
InvestingPro Tips highlight that Tempest holds more cash than debt on its balance sheet, which could be crucial for funding its upcoming Phase 3 trial. However, the company is quickly burning through cash and is not profitable over the last twelve months, underscoring the financial challenges noted in the Scotiabank report. The stock's recent performance, trading near its 52-week low, aligns with the analyst's concerns about potential difficulties in raising capital through traditional equity markets.
For investors seeking a deeper understanding of Tempest Therapeutics' financial health and market position, InvestingPro offers 14 additional tips, providing a comprehensive view of the company's prospects in the competitive biopharmaceutical landscape.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.